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Abstract
Antimicrobial peptides (AMP) secreted by the granular glands of frog skin have
been widely reported to exhibit strong bacteriostatic and bactericidal activities.
Many of them have been documented with potent antiproliferative effects on
multiple cancer cells, many studies also suggested that AMPs exert their functions
via disrupting cell membranes. However, whether and how other cell death induc-
tion mechanism is involved in mammalian cancer cells has rarely been investi-
gated. In this study, a novel AMP named Dermaseptin‐PS1 was isolated and
identified from Phyllomedusa sauvagei, it showed strong antimicrobial activities
against three types of microorganisms. In vitro antiproliferative studies on human
glioblastoma U‐251 MG cells indicated that Dermaseptin‐PS1 disrupted cell mem-
branes at the concentrations of 10−5 M and above, while the cell membrane
integrity was not affected when concentrations were decreased to 10−6 M or
lower. Further examinations revealed that, at the relatively low concentration
(10−6 M), Dermaseptin‐PS1 induced apoptosis through mitochondrial‐related sig-
nal pathway in U‐251 MG cells. Thus, for the first time, we report a novel frog
skin derived AMP with anticancer property by distinct mechanisms, which largely
depends on its concentration. Together, our study provides new insights into the
mechanism‐illustrated drug design and the optimisation of dose control for cancer
treatment in clinic.
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1 | INTRODUCTION
Glioblastoma, as the major type of primary brain tumour, has the
worst prognosis among all malignancies. However, due to the abnor-
mal cellular composition and rapid escape from therapeutic agents,
very limited progress has been made in the last few decades for
effectively killing or controlling glioblastoma cells. To date, combining
the radiotherapy and chemotherapy with surgery remains the main-
stream strategy for the treatment of glioblastoma.1,2 Therefore,
development of novel drugs for specifically targeting human glioblas-
toma has promising perspective.
The de novo design of AMPs from natural sources has brought
much attention, as many of these peptides share the properties of
being linear, cationic and α‐helical, which are essential for the initial
attraction of them to the negatively charged cell membrane for con-
sequent membrane disruption.3 It is well established that prokaryoticQilin Long and Lei Li equally contributed to this work and share the first authorship.
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cell membrane and eukaryotic mitochondrial membrane possess high
transmembrane potentials. By contrast, the zwitterionic phospholipid,
which is the main composition of eukaryotic membrane, possesses
low transmembrane potential.4-7 As a consequence, the majority of
AMPs prefer to corrupt the prokaryotic membrane and eukaryotic
mitochondrial membrane rather than the eukaryotic membrane.
Thus, those AMPs with distinct membrane‐penetration mechanism
on tumour cells that allows the receptor‐regulated internalisation,
followed by induction of programmed cell death, could serve as
unique and supplementary options for cancer therapy.
Apoptosis is a programmed process that plays a pivotal role in
modulating physiological and pathological cell death.8 Extensive scru-
tiny has been focused on the investigation of apoptosis‐related can-
cer research, in particular the disorder of cancer cells to undergo
apoptosis could lead to severe malignant progression and
chemotherapy resistance.9 The whole process of apoptosis com-
posed of either of the two distinguished signalling transduction path-
ways and a number of proteins that located in multiple organelles.10
Compared with death receptor (extrinsic) pathway, the mitochondrial
(intrinsic) pathway of apoptosis is most commonly deregulated in
cancer cells, and most stimuli induce the initiation of apoptosis
through mitochondrial signalling that governs the release of cyto-
chrome c to the cytosol, which in response regulates the activity of
caspase protease.11,12 Upon activation, caspases cleave a number of
proteins, resulting in cell death, and the alterations in biochemistry
and morphology occur.13
In this study, using human glioblastoma U‐251 MG cells, we
investigated the tumour suppression effect of the novel isolated
AMP Dermaseptin‐PS1 from P. sauvagei. We provide the evidence
that the concentration is critical for anticancer agents to exert bio-
logical functions through differentiated mechanisms, which support
the further drug design and development for targeting the interven-
tion of mitochondrial apoptosis in cancer therapy.
2 | MATERIALS AND METHODS
2.1 | Specimen biodata and skin secretion
harvesting
Specimens of P. sauvagei (n = 3, two males 5 cm snout‐to‐vent
length, one female 7 cm snout‐to‐vent length), originally from South
America, were obtained from a commercial source in the United
States. The skin secretion produced by the holocrine glands of frogs
was obtained by mild transdermal electrical stimulation (5 V, 50 Hz,
4 ms plus width) as previously described.14 Secretions were then col-
lected by rinsing with distilled deionized water and were subjected
to snap frozen with liquid nitrogen, lyophilized and stored at −20°C
prior to use. Sampling of skin secretion was performed by Mei Zhou
under UK Animal (Scientific Procedures) Act 1986, project license
PPL 2694, issued by the Department of Health, Social Services and
Public Safety, Northern Ireland. Procedures had been vetted by the
IACUC of Queen's University Belfast and approved on 1 March
2011.
2.2 | “Shotgun” cloning of novel Dermaseptin‐like
peptide encoding cDNAs from lyophilized skin
secretion
Five milligrams of lyophilised P. sauvagei secretion powder were dis-
solved in 1 mL cell Lysis/Binding buffer to isolate polyadenylated
mRNA by using magnetic oligo‐dT beads in Dynabeads® mRNA
DIRECT™ Kit (Dynal Biotech, Liverpool, UK). Then the reverse‐tran-
scribed cDNA library was subjected to 3′‐RACE PCR procedures to
acquire the full length of preproprotein nucleic acid sequences using
a SMART‐RACE kit (Clontech, Palo Alto, CA, USA) essentially as
described by the manufacturer. Briefly, the 3′‐RACE reactions
employed a UPM primer (supplied with the kit) and degenerate
sense primers (S1; 5′‐ACTTTCYGAWTTRYAAGMCCAAABATG‐3′,
Y = C + T, W = A + T, R = A + G, M = A + C, B = T + C + G) that
was designed to a segment of the 5′‐untranslated region of phylloxin
cDNA from Phyllomedusa bicolor (EMBL accession no. AJ251876)
and the opioid peptide cDNA from Pachymedusa dacnicolor (EMBL
accession no. AJ005443).15 PCR cycling procedures were carried out
as follows: initial denaturation step: 90 seconds at 94°C; 35 cycles:
denaturation 30 seconds at 94°C, primer annealing for 30 seconds
at 58°C; extension for 180 seconds at 72°C. PCR products were gel‐
purified and cloned using a pGEM‐T vector system (Promega Corpo-
ration, Southampton, UK), and selected samples were sequenced by
an ABI 3730 automated sequencer.
2.3 | Identification and structural characterisation
of the novel Dermaseptin‐like peptide
An aliquot sample of the lyophilised P. sauvagei skin secretion was
dissolved in 1 mL of trifluoroacetic acid (TFA)/water (0.05:99.95, v/v)
and clarified by centrifugation. One millilitre of clear supernatant
was carefully decanted and pumped directly into a reverse‐phase
HPLC column (C‐18, 300 Å, 5 μm, 4.6 mm × 250 mm; Phenomenex,
Cheshire, UK). The elution gradient formed from 0.05/99.5 (v/v) TFA/
water to 0.05/19.95/80.0 (v/v/v) TFA/water/acetonitrile in 240 min-
utes at a flow rate of 1 mL/min and the effluent was detected by
UV absorbance at 214 nm and 280 nm. An automatic fraction collec-
tor (GE Healthcare, Little Chalfont, UK) was used to collect the frac-
tions at 1‐minute interval. All fractions were interrogated by matrix‐
assisted laser desorption ionisation time‐of‐flight (MALDI‐TOF) mass
spectrometry in positive detection mode using alpha‐cyano‐4‐hydro-
xycinnamic acid (CHCA) as matrix. The fractions with masses coinci-
dent with the putative peptide from molecular cloning were
subjected to Liquid Chromatography Quadruple (LCQ)‐Fleet electro-
spray ion‐trap mass spectrometer (Thermo Fisher Scientific, San
Francisco, CA, USA) for primary structural analysis.
2.4 | Solid‐phase peptide synthesis
Following unambiguous confirmation of the primary structure
through both molecular cloning strategy and LCQ‐Fleet mass spec-
trometry, the peptide was chemically synthesised by Tribute™
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automated solid phase peptide synthesizer 4 (Protein Technologies,
Tucson, AZ, USA). The synthesised peptide replicates were then
purified by reverse‐phase HPLC and confirmed by MALDI–TOF mass
spectrometry prior to use.
2.5 | Peptide secondary structure determination via
circular dichroism
JASCO J‐815 circular dichroism (CD) spectrometer (Jasco, Essex, UK)
was used to detect the secondary structure of Dermaseptin‐PS1.
Peptide was dissolved in (a) 10 mmol/L NH4AC, (b) 50% (v/v) trifluo-
roethanol (TFE)‐10 mmol/L NH4AC to reach a final concentration of
100 μmol/L before transferred and measured in a 0.1 cm high preci-
sion quartz cell (Hellma Analytics, Essex, UK). The wavelengths used
were from 190 nm to 260 nm with a scanning speed of 200 nm/min,
and the bandwidth and data pith were 1 nm and 0.5 nm respec-
tively. CD data are expressed as the molar ellipticity [θ] in deg/cm2/
dmol at respective wavelength (nm), which is calculated from the
measured Ellipticity (θ, in medg) using the equation [θ] = θ/(10 × c × l)
where c is the molar concentration of the sample (mol/L) and l is the
cuvette path length in centimetre (cm). DICHROWEB webserver
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) was used to esti-
mate the contents of different secondary structures.16-18
2.6 | Antimicrobial and haemolytic assays
The antimicrobial assays for evaluating the minimum inhibitory con-
centration (MIC) and the minimum bactericidal concentration (MBC)
of the peptide were performed by using the Gram‐positive bacterium
Staphylococcus aureus (S. aureus) (NCTC 10788), the Gram‐negative
bacterium, Escherichia coli (E. coli) (NCTC 10418) and the yeast, Can-
dida albicans (C. albicans) (NCPF 1467). The haemolytic activity of
Dermaseptin‐PS1 was assessed using a 4% suspension of horse red
blood cells (supplied by TCS Biosciences Ltd, Botolph Claydon, Buck-
ingham, UK) in phosphate‐buffered saline (PBS). The detailed proce-
dures were described previously.19
2.7 | Cell line, cell culture and chemicals
Human glioblastoma cells, U‐251 MG, were purchased from the cell
bank of European Collection of Authenticated Cell Cultures (ECACC‐
09063001) in 2015. The cells were authenticated by ECACC cell bank
using short tandem repeat polymorphism analysis and were expanded
and stored in liquid nitrogen upon receipt, and each aliquot was pas-
saged for fewer than 6 months in our laboratory. Once resuscitated,
the cell line was authenticated by monitoring the cell morphology. U‐
251 MG was cultured in Dulbecco's Modified Eagle's Medium (DMEM)
(Invitrogen, Paisley, UK) containing 2 mmol/L Glutamine (gibco®, Pais-
ley, UK), 1% non‐essential amino acids (NEAA) (gibco®), 1 mmol/L
sodium pyruvate (NaP) (Thermo Fisher Scientific), 10% foetal bovine
serum (FBS) (gibco®) and 1% antibiotics (100 U/mL penicillin, 0.1 mg/
mL streptomycin; gibco®) at 37°C with 5% CO2. Etoposide was pur-
chased from Tocris Bioscience, Bristol, UK (Cat: 1226), and Z‐VAD‐
FMK was purchased by Dr Mei Chen in WWIEM, Queen's University
Belfast from InvivoGen, Toulouse, France (Cat: tlrl‐vad).
2.8 | MTT cell proliferation and LDH cell membrane
integrity evaluations
Five thousand cells/well in 100 μL full growth DMEM medium were
planted into 96‐well plates and allowed to attach for 24 hours. Cells
were starved by serum‐free medium for 6 hours before treated with
peptide concentration gradient (10−4 to 10−9 M, n = 5) for 24 hours.
After which, 10 μL of 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazo-
lium bromide (MTT) solution was added to each well prior to another
4 hours incubation, the optical density (OD) values were measured at
570 nm by using EL808 TM Absorbance Microplate Reader.
The cell membrane integrity was measured by using lactate
dehydrogenase (LDH) assay with Pierce LDH Cytotoxicity Assay Kit
(Thermo Scientific, Loughborough, UK) according to the manufac-
turer's instruction with the same treatment conditions.
2.9 | Western blotting
Protein lysates extracted from cells were used to detect protein
expression levels of caspase 3 (Cell Signaling, Stillorgan, Ireland;
#9662), caspase 8 (Cell Signalling; #9746), FADD (Cell Signalling;
#2782), caspase 9 (Cell Signalling; #9508), Apaf‐1 (Cell Signalling;
#8723), Bcl‐2 (Cell Signalling; #4223), Bax (Cell Signalling; #5023), Bak
(Cell Signalling; #3814), Bad (Cell Signalling; #9292), Phospho‐Bad
(Ser112) (Cell Signalling; #9291), Phospho‐p53 (Ser15) (Cell Signalling;
#9284), p53 (Cell Signalling; #2524), cytochrome c (Cell Signalling;
#4272), COX IV (Cell Signalling; #4844), β‐Tubulin (Cell Signalling;
#2146) and GAPDH (Cell Signalling; #5174). The immunoblotting pro-
tocol was previously described.19
2.10 | Annexin V apoptosis fluorescence imaging
Cells were planted into 4‐well chamber‐slides (Falcon® Culture Slides,
VWR, UK) at a density of 6 × 104 cells/mL/well and allowed to attach
for 24 hours. After 6 hours starvation, cells were treated with peptide
concentration gradient (10−4 to 10−7 M) for 16 hours. Then, cells were
dyed with FITC‐Annexin V Apoptosis Detection Kit I (BD Pharmin-
gen™; BD Biosciences, Berkshire, UK) according to the manufacturer's
instruction. After the staining, 4% paraformaldehyde (Alfa Aesar, Ward
Hill, MA, USA) was used to fix cells and one drop of anti‐fade mount-
ing medium (Thermo Fisher, UK) was added to each well before cover-
slip seal using nail polish. The slides were immediately analysed by
Leica DMi8 fluorescent microscope imaging system.
2.11 | RNA extraction and quantitative real‐time
PCR analysis
Cells were planted into 6‐well plates at a density of 2 × 105 cells/2 mL/
well and allowed to attach for 24 hours. After 6 hours starvation, cells
were treated by peptide concentration gradient (10−4 to 10−7 M) for
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16 hours. Then, 500 μL of TRIzol® Reagent (Thermo Fisher, Loughbor-
ough, UK) was added into each well and RNA was extracted by 100 μL
chloroform and purified by 200 μL isopropanol. The solutions were cen-
trifuged at 12 000 × g for 10 minutes and the supernatant was
removed before the pellets were washed with 75% ethanol. After
which, the RNA pellets were resuspended in 20 μL diethyl pyrocarbon-
ate (DEPC) water and quantified using Nanodrop Onec system (Ther-
mofisher, UK). One microgram RNA from each sample was reverse
transcribed by using iScript™ cDNA Synthesis Kit (Bio‐Rad, Dublin, Ire-
land) according to the manufacturer's instructions. Real‐time PCR ampli-
fication was performed with SYBR® Select Master Mix (Thermofisher)
on an CFX Connect™ Real‐Time PCR Detection System (Bio‐Rad) with
PCR procedures under the following programme: 1 cycle at 95°C for
3 minutes; 45 cycles at 95°C, 20 seconds and 60°C for 1 minute; 1
cycle at 95°C for 1 minute and 55°C for 1 minute; 80 cycles at 55°C for
10 seconds and increase set point temperature after cycle 2 by 0.5°C.
The melt curve data were collected and analysed. The relative mRNA
abundance normalized to 18S rRNA levels was determined with the
ΔΔCt (cycle threshold) method after amplification. Data are represented
as mean ± SD. Sequences for primers used in this study are listed in
Table 1.
2.12 | Cytosolic and mitochondrial protein
extraction
About 5 × 106 cells were treated with 500 μL Mitochondrial Protein
Isolation Buffer (2 μL 100× protease inhibitors added) (AMRESCO,
Lutterworth, Leicestershire, UK) and incubated on ice for 10 min. The
cell membrane was lysed by sucking the solution back and forth for 20
times with a 26 ½ G needle. The cell debris including the unbroken
nuclei was removed through centrifugation at 1000 × g, 4°C for
10 minutes. The cytoplasmic proteins were collected from the super-
natant after the solution was further centrifuged at 15 000 × g, 4°C
for 20 minutes. The mitochondrial proteins were collected from the
pellet treated with 100 μL of Mitochondrial Protein Isolation Buffer.
2.13 | Statistical analysis
All results are presented as mean ± SEM determined by two‐tailed
Student's t tests or one‐way ANOVA. Pair comparisons of the means
were made, and P < 0.05 was taken as a significant difference. The
Bonferroni method was used to adjust the observed significance
levels for the fact the multiple contrasts were being tested.
3 | RESULTS
3.1 | Identification, characterisation and chemical
synthesis of the novel peptide Dermaseptin‐PS1 from
P. sauvagei
The cDNA library was constructed using the skin secretion of P. sau-
vagei, from which, the cDNA encoding the biosynthetic precursor of
Dermaseptin‐PS1 was consistently cloned (n = 6). The coding region
of the cDNA composed of 79 amino acids. It consists of four domains:
a 19‐residue putative signal peptide domain located at the N‐terminus
of the reading frame, a 23‐residue acidic spacer domain which is fol-
lowed by the canonical propeptide convertase processing site Lys‐Arg
(K‐R), a 31‐mer mature peptide domain with glycine‐76 acts as an
amide donor, and a C‐terminal untranslated region. The predicted
mature peptide sequence was determined as: ALWKTMLKKLGTVAL-
HAGKAALGAVADTISQ‐NH2 (Figure 1A). Via BLAST and Clustal
Omega sequence alignment analysis, the sequence of the mature pep-
tide showed high similarity with Dermaseptin‐SVII (EMBL accession
number: AJ564792), Dermaseptin‐SII (P80278), Dermaseptin‐SI
(P80277) and Dermaseptin‐SVIII (AJ564792) from P. sauvagei, which
suggested that this novel peptide belongs to the Dermaseptin family,
and we named it as Dermaseptin‐PS1 (Figure 1B).
The fractionated skin secretion of P. sauvagei by reverse‐phase
(rp) HPLC (Figure 1C) was subjected to MALDI‐TOF mass spec-
trometry analysis, the fractions that share the identical molecular
weight with the deduced mature peptide from cloning were further
examined by LCQ‐Fleet electrospray ion‐trap mass spectrometer for
primary structure identification, as Figure 1D shown, the mature
sequence of Dermaseptin‐PS1 was unequivocally confirmed with
the C‐terminal amidation after analysis of multiply charged pre‐cur-
sor fragmentation spectra using Max‐Ent3 software (Waters). The
nucleotide sequence of the encoding cDNA precursor of Der-
maseptin‐PS1 from the skin secretion of P. sauvagei, has been
deposited to EMBL Nucleotide Sequence Database under the
accession code: LT840240.
TABLE 1 The primer sequences used in conducting the qPCR experiments
Target protein Sense primer Antisense primer
APAF‐1 5′‐CCTGTTGTCTCTTCTTCCAGTGT‐3′ 5′‐AAAACAACTGGCCTCTGTGG‐3′
TNFR1 5′‐TGCCAGGAGAAACAGAACAC‐3′ 5′‐TCCTCAGTGCCCTTAACATTC‐3′
Fas 5′‐ACTCACCAGCAACACCAAG‐3′ 5′‐TCATGACTCCAGCAATAGTGG‐3′
Bax 5′‐GAGCAGATCATGAAGACAGGG‐3′ 5′‐AGTAGAAAAGGGCGACAACC‐3′
Bcl‐2 5′‐GTGGATGACTGAGTACCTGAAC‐3′ 5′‐CCTGCAGCTTTGTTTCATGG‐3′
Bid 5′‐ATTAACCAGAACCTACGCACC‐3′ 5′‐TCTAGGAACGCTGTTGACATG‐3′
Caspase 8 5′‐ATCCTGAAAAGAGTCTGTGCC‐3′ 5′‐ATTCCTGTCCCTAATGCTGTG‐3′
Caspase 9 5′‐CCTAGAAAACCTTACCCCAGTG‐3′ 5′‐CACGGCAGAAGTTCACATTG‐3′
18S 5′‐CGGCTACCACATCCAAGGAA‐3′ 5′‐AGCTGGAATTACCGCGGC‐3′
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For further biological function investigations, the Dermaseptin‐
PS1 peptide replicates were chemically synthesised by solid‐phase
Fmoc strategy through Tribute™ automated solid‐phase peptide syn-
thesizer 4 (Protein Technologies). The crude synthetic products were
purified and confirmed by rp‐HPLC and MALDI‐TOF MS (Figure S1),
respectively, to achieve the purity >95%.
3.2 | Secondary structure determination using CD
analysis
Circular dichroism was used to investigate the secondary structures
of Dermaseptin‐PS1 in 10 mmol/L ammonium acetate (NH4Ac)
(mimicking aqueous environment) and 50% TFE‐10 mmol/L NH4Ac
solution (mimicking the hydrophobic environment of cell membrane)
solutions (Figure 1E). The generated data were analysed by DICRO-
WEB webserver. In 10 mmol/L NH4Ac solution, Dermaseptin‐PS1
showed a mixed conformation of random coil (48%) and β‐sheet
(48%) with a negative band presented at 198 nm. By contrast, in
50% TFE‐10 mmol/L NH4Ac solution, the α‐helical structure was
increased to 25%, and random coil increased to 60%, while β‐sheet
decreased to 15% (Table 2). The results suggested that the Der-
maseptin‐PS1 was partially structured to a membrane‐penetrated
β‐sheet structure in membranes mimic surroundings, but largely
remained unstructured in aqueous solution, indicating that
A
B
C
D
E
F IGURE 1 Primary structure
identification, determination and analysis
of Dermaseptin‐PS1 from Phyllomedusa
sauvagei (A) nucleotide and translated
open‐reading frame amino acid sequences
of cloned cDNA encoding the
Dermaseptin‐PS1 precursor from
P. sauvagei skin secretion (EMBL accession
number: LT840240). The putative signal
peptide is double‐underlined, the mature
peptide is single‐underlined and the stop
codon is indicated by an asterisk. (B)
Alignment of cDNA deduced mature
Dermaseptin‐PS1 sequence with
dermaseptin peptides from P. sauvagei
species. The identical and conservative
residues are indicated by asterisks (*) and
full stop (.)/colon (:), respectively. (C) rp‐
HPLC chromatogram of P. sauvagei skin
secretion with an arrow indicating the
retention time (at 123 min) of
Dermaseptin‐PS1. The detection
wavelength was 214 nm with a flow rate
of 1 mL/min in 240 min. (D) Predicted
single‐ and double‐charged b‐ and y‐ion
series arising from LCQ MS/MS
fragmentation of Dermaseptin‐PS1. The
truly observed fragment ions following
actual fragmentation are shown in red
(b‐ions) and blue (y‐ions) typefaces
respectively. (E) The CD spectra recorded
for the purified synthetic Dermaseptin‐PS1
in (a) 10 mmol/L ammonium acetate
(NH4Ac) water solution and (b) 50% 2,2,2‐
trifluoroethanol (TFE)‐50% NH4Ac water
solution. The molar ellipticity was plotted
against wavelength and the tested peptide
concentration was 100 μmol/L
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Dermaseptin‐PS1 did not adopt a typical antimicrobial structure (α‐
helix or β‐sheet) in physiological condition, and therefore, acting as a
ligand for receptor activation might be the main underlying mecha-
nism of its bioactivity.
3.3 | Dermaseptin‐PS1 exhibited moderate
antimicrobial activity against typical strains
As Dermaseptin family peptides have been widely reported to
possess strong antimicrobial activities,20-22 we tested whether
Dermaseptin‐PS1 can retard the reproduction of microorganisms.
The results showed that the novel peptide Dermaseptin‐PS1
exhibited moderate antimicrobial activities against S. aureus (Fig-
ure 2A), E. coli (Figure 2B) and C. albicans (Figure 2C) with rela-
tively low haemolytic effect (<20% at 10−5 M) (Figure 2D). The
MIC values for the Gram‐positive (S. aureus) and the Gram‐nega-
tive bacteria (E. coli) were 10−5 M, which is higher than the
10−4 M against the yeast (C. albicans), and the MBC values of
Dermaseptin‐PS1 against S. aureus, E. coli were 10−4 M, no MBC
value was detected against C. albicans.
3.4 | Dermaseptin‐PS1 displayed antiproliferative
activity in glioblastoma U‐251 MG cells
Many of the AMPs, with the inherent characteristics of being linear,
cationic and amphipathic, have been proved to exert antiproliferative
capacities through non‐specific interaction with eukaryotic cell
TABLE 2 Secondary structure analysis of Dermaseptin‐PS1 by
using DICHROWEB online server
Percentage (%) α‐helix β‐sheet Random coil
NH4Ac 4 48 48
50% TFE +NH4Ac 25 15 60
F IGURE 2 Antimicrobial activity and haemolytic effect of Dermaseptin‐PS1. The minimum inhibitory concentrations of Dermaseptin‐PS1
against (A) Staphylococcus aureus, (B) Escherichia coli and (C) Candida albicans. The minimum bactericidal concentration (MBC) values against
S. aureus, E. coli were 10−4 M and no MBC value was detected against C. albicans. Data were analysed with unpaired Student's t test using
GraphPad Prism 5 software. Values are the mean ± SEM for three independent experiments. Veh represents vehicle control, *P < 0.05,
**P < 0.01 and ***P < 0.001 vs vehicle control. (D) Haemolytic activity of Dermaseptin‐PS1 following incubation with horse erythrocytes for
2 h. Data were analysed with unpaired Student's t test using GraphPad Prism 5 software. Values are the mean ± SEM for three independent
experiments. P represents positive control, ***P < 0.001 vs positive control (10% Triton X‐100)
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membranes,23 while internalisation initiated apoptosis induction has
also been reported to act as the major mechanism of anticancer
functions.24 Thus, we tested the antiproliferative activity of Der-
maseptin‐PS1 using different cell lines, and the results (Figure 3 and
Figure S2) indicated that the glioblastoma U‐251 MG cells have low-
est survival rates after Dermaseptin‐PS1 treatment. MTT cell viability
examinations revealed that Dermaseptin‐PS1 showed strong antipro-
liferative effects on all tested cancer cell lines and human mammary
epithelial cell (HMEC) at 10−4 M and 10−5 M concentrations,
however, at the concentration of 10−6 M, a moderate antiprolifera-
tion activity was observed in U‐251 MG cells (cell viability around
65%) after Dermaseptin‐PS1 treatment (Figure 3A), while the cell
viabilities of other cancer cells and HMEC cells were not affected
(Figure S2), which reminded us that Dermaseptin‐PS1 might have
specific cell death induction mechanism in U‐251 MG cancer cells at
10−6 M. In addition, when the tested peptide concentration
decreased to 10−7 M or lower, the antiproliferative effect of Der-
maseptin‐PS1 on all tested cell lines was completely abrogated. To
F IGURE 3 Dermaseptin‐PS1 display
antiproliferative activity against U‐251 MG
cell line. A, The antiproliferative effect of
human neuronal glioblastoma cells, U‐251
MG cell line after the treatment of
Dermaseptin‐PS1 gradient (10−4 to
10−9 M) for 24 h. The calculated IC50
value was 5.419 μmol/L. Data were
analysed with unpaired Student's t test
using GraphPad Prism 5 software. Values
are the mean ± SEM for three independent
experiments. Veh represents vehicle
control, ***P < 0.001 vs vehicle control. B,
The morphology changes of U‐251 MG
cells after the treatment of Dermaseptin‐
PS1 gradient (10−4 to 10−7 M) for 24 h.
The images were observed by a
magnification factor ×200. C, Lactate
dehydrogenase (LDH) release from U‐251
MG cells after the treatment of
Dermaseptin‐PS1 gradient (10−4 to
10−8 M) for 24 h. Data were analysed with
unpaired Student's t test using GraphPad
Prism 5 software. Values are the
mean ± SEM for three independent
experiments. ***P < 0.001 vs negative
control
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further explore whether the cell viability reduction was caused by
the cancer cell membrane disruption, we employed phase contrast
microscopy and lactate dehydrogenase (LDH) assay to assess the cell
membrane integrity in U‐251 MG cells. As shown in Figure 3B, after
24 hours treatment of 10−4 and 10−5 M Dermaseptin‐PS1, the
U‐251 MG cells distributed sparsely, lost cell‐cell contact, became
rounded, and much more cellular debris was observed compared
with control group and 10−6 M, 10−7 M groups, which appeared to
retain an integral cell shape. This suggested that the cell mem-
branes ruptured by high concentrations of Dermaseptin‐PS1, while
when the concentration decreased to 10−6 M and lower, the mor-
phological integrity of the cells was not affected. Moreover, as has
been documented that one of the key signatures of cells undergo-
ing necrosis is the cell membrane permeabilisation, which could be
simply detected through LDH release assay.25 Therefore, we per-
formed LDH assay to assess whether at high concentration
(10−5 M) Dermaseptin‐PS1 kills cells via necrosis. The results (Fig-
ure 3C) showed that, at the concentration of 10−4 M, Dermaseptin‐
PS1 caused more than 20% LDH release from the cells, and
10−5 M concentration also triggered a more than 15% leakage. In
contrast, 10−6 to 10−8 M did not render LDH release, indicating a
obvious necrosis induction mechanism by Dermaseptin‐PS1 at the
concentration of 10−5 M and above. Therefore, these results
prompt us to suggest that Dermaseptin‐PS1 may have a distinct
U‐251 MG cells killing mechanism, which is mainly in a concentra-
tion‐related manner.
3.5 | Dermaseptin‐PS1 induced U‐251 MG cell
death at 10−6 M via induction of apoptosis
Apoptosis and autophagy are two major programmed cell‐destruc-
tive processes, both of them could be elicited by exogenous stress
or ligand.26 We firstly used Western blotting to examine whether
Dermaseptin‐PS1 caused cell viability decrease was through the
activation of either or both of apoptosis and autophagy. As the
dose assessment shown in Figure 4A, Dermaseptin‐PS1 treatment
at 10−6 M elevated the expression level of cleaved caspase 3.
Quantitative analysis normalised by GAPDH revealed that, com-
pared with negative control, 10−8 M, 10−7 M, 10−5 M and 10−4 M,
the 10−6 M and etoposide (positive control) treatments have signif-
icant higher expression of the apoptosis marker cleaved caspase 3,
and the total caspase 3 protein level was not affected. Additional
time‐course assessment indicated that 10−6 M Dermaseptin‐PS1
induced the highest expression of cleaved caspase 3 after 16 hours
and/or 24 hours treatment (Figure 4B). Based on these observa-
tions, we treated the U‐251MG cells using 10−6 M concentration
of Dermaseptin‐PS1 for 16 hours with or without Z‐VAD‐FMK, a
caspase inhibitor which could inhibit the induction of apoptosis.27
The results (Figure 4C) showed that, pre‐Z‐VAD‐FMK treatment
completely abrogated Dermaseptin‐PS1 and etoposide‐induced ele-
vation of cleaved caspase 3, suggesting the induction of apoptosis
by Dermaseptin‐PS1 at 10−6 M in U251‐MG cells. However, autop-
hagy activation assessment revealed that, compared with positive
control (Brefeldin A or Earle's balanced salt solution), the LC3‐II/
LC3‐I ratio did not increase after time‐course treatment of Der-
maseptin‐PS1 on U‐251 MG cells (Figure S3). Thus, we suggested
that Dermaseptin‐PS1 could activate apoptosis, rather than autop-
hagy, to induce programmed cell death at the concentration of
10−6 M.
Furthermore, Annexin V‐based luminescent images showed that
exposure of U‐251 MG cells at 10−6 M Dermaseptin‐PS1 or etopo-
side could elicit strong Annexin V signals (green), which were mostly
localised on the membrane, while the propidium iodide (PI) was
barely seen (red) in the nucleus. However, exposure of the cells to
10−4 M or 10−5 M Dermaseptin‐PS1 significantly diminished the
Annexin V signals, by contrast, the nuclear PI staining signals were
markedly elevated. While, 10−7 M Dermaseptin‐PS1 caused neither
Annexin V nor PI signal increase (Figure 4D).
Next, we examined the related marker genes for both intrinsic
and extrinsic cascades of apoptosis at transcriptional level. As
shown in Figure 4E, the pro‐apoptotic genes were increased signif-
icantly, while the anti‐apoptotic Bcl‐2 gene remained unaltered,
which lead to the elevation of Bax/Bcl‐2 ratio. The up‐regulation
of Bax/Bcl‐2 ratio contributes to the activation of apoptotic
cascade.28
Together, we confirmed that Dermaseptin‐PS1 disrupted the U‐
251 MG cell membranes at 10−5 M and higher concentrations, and
induced apoptosis at 10−6 M to exert the antiproliferative effects.
F IGURE 4 Dermaseptin‐PS1 induced U‐251 MG cell death at 10−6 M via apoptosis. Western blot analysis was performed on U‐251
MG cells to test the expression of cleaved caspase 3 and caspase 3 after the treatment of (A) NC, 20 μmol/L, 15 μmol/L and 10 μmol/L
etoposide and 10−4 to 10−8 M Dermaseptin‐PS1 for 24 h; (B) 10−6 M Dermaseptin‐PS1 and 20 μmol/L etoposide for indicated times; (C)
20 μmol/L Z‐VAD‐FMK for 2 h subsequent to 20 μmol/L etoposide and 10−6 M Dermaseptin‐PS1 treatment for 16 h. The detection of
GAPDH protein was used as an internal control. The signal intensity was quantified by Image Lab software and GraphPad Prism 5
software was used for statistical comparison. NC, negative control. *P < 0.05, **P < 0.01 and ***P < 0.001 vs negative control. (D) The
fluorescent microscopy images showing FITC‐annexin V positive membranes, propidium iodide (PI)‐stained nuclei and a merge image.
The images were captured from a population of U‐251 MG with the exposure to Dermaseptin‐PS1 gradient (10−4 to 10−7 M) or
20 μmol/L etoposide for 16 h. Scale bar = 25 μm. (E) The mRNA levels of apoptosis‐related genes were analysed by real‐time PCR. The
qPCR analysis performed on U‐251 MG cells by the treatment of 10−6 M Dermaseptin‐PS1 for 16 h. The sequences of pro‐apoptotic
genes are displayed in Table 1. The mRNA expression of 18S was used as a calibration standard. Data were analysed with one‐way
ANOVA using GraphPad Prism 5 software. Values are the mean ± SEM for three independent experiments. ***P < 0.001 vs negative
control
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3.6 | Dermaseptin‐PS1 induced U‐251 MG cell
apoptosis through intrinsic cascade
To investigate the specific intracellular mechanism by which Der-
maseptin‐PS1 exerts the apoptosis induction effect, we examined
the marker genes that related to the intrinsic or extrinsic apoptotic
cascades. As shown in Figure 5, the extrinsic cascade related Cas-
pase 8 and Fas‐associated protein with death domain (FADD)
remained unchanged after 10−6 M Dermaseptin‐PS1 treatment for
16 hours. Thus, we suggested that the intrinsic signalling might be
crucial for executing Dermaseptin‐PS1 triggered apoptosis.
Then, we examined whether the intrinsic apoptotic signalling was
involved. After treated with 10−6 M Dermaseptin‐PS1 or 20 μmol/L
etoposide (Figure 6A), the expression levels of cleaved caspase 9,
apoptotic protease activating factor 1 (Apaf‐1), Bcl2‐associated X
protein (Bax), Bcl‐2 homologous antagonist/killer (Bak) and phosphate
p53 at Ser15 were remarkedly increased. While the expression of
Bcl‐2‐associated death promoter (Bad) remained stable, but the
phosphorylation form of Bad, phosphate Bad at Ser112, was signifi-
cantly decreased after 16 hours treatment of Dermaseptin‐PS1.
Moreover, the protein expression of Bcl‐2 showed the same trend in
the mRNA alteration.
Following on from this, we directly detected the cytochrome c
levels in both cytoplasm and mitochondria, as shown in Figure 6B,
after Dermaseptin‐PS1 treatment for 16 hours, the cytosolic cyto-
chrome c level markedly elevated compared with the vehicle control,
which suggested the mitochondrial‐related cytochrome c release,
reflecting that the intrinsic apoptotic pathway had been activated.
4 | DISCUSSION
Although, in the past decades, significant progress has been made
for the treatment of cancers via induction of apoptosis, many
challenges still remain, which are not only in the field of expanding
the application of targeting apoptosis in multiple cancer cells, but
also preventing cancer cells resistant to therapies.12 A novel type
of drugs, named “BH‐3 mimetics,” has been developed and applied
clinically, they directly inhibit Bcl‐2 family members for apoptosis
activation, with the aim of overcoming the upstream proteins initi-
ated therapeutic resistance.29 However, these intrinsic apoptotic
pathway targeted drugs also face the problems that toxicities need
to be improved in the meantime of keeping or enhancing the
potency on killing cancer cells.30-32 In this study, we focused on
investigating the potential anticancer mechanism of the novel char-
acterised peptide Dermaseptin‐PS1 on malignant glioblastoma U‐
251 MG cells.
Our data confirmed that Dermaseptin‐PS1 possessed strong
antimicrobial (E. coli, S. aureus and C. albicans), anticancer (U‐251
MG) and haemolytic activities at the concentration of 10−5 M,
through the morphological (Figure 3B) and LDH (Figure 3C) analy-
sis, we presumed that these effects were resulted from necrosis
caused by Dermaseptin‐PS1, which is a non‐specific cell mem-
brane disruption mechanism, and this could be further unambigu-
ously determined by the most reliable transmission electron
microscopic detection.33 While the U‐251 MG cell viability
decrease after being exposed to 10−6 M peptide attracted our
attention, as all the results implied that no mechanic cell mem-
brane damage was likely to be involved. As a consequence, we
examined the apoptosis activation. One of the interesting issues
we observed was that, almost all mRNA levels of the measured
apoptotic related genes (intrinsic and extrinsic) increased signifi-
cantly after treatment of 10−6 M Dermaseptin‐PS1, but we barely
seen the up‐regulation of protein level of cleaved caspase 8, the
main executor of extrinsic pathway. As the fact that caspases
exist in the form of zymogens, their activities depend largely on
cleaving the zymogens to the active forms,34 and thus, compared
with transcriptional‐regulation, post‐translational regulations are
more essential for the caspases activity. In addition, the expres-
sion of FADD had no significant changes. Thus, we deduced that
the extrinsic pathway is not involved in the Dermaseptin‐PS1
induced apoptosis. Nevertheless, the detailed mechanism associ-
ated with why the up‐regulated mRNA level of extrinsic targets
has not contributed to the active form of caspase 8 warrants fur-
ther investigations.
In addition, the marker proteins from the intrinsic apoptotic
cascade (Figure 6A) indicated that the intrinsic apoptotic cas-
cade was responsible for low concentration of Dermaseptin‐PS1
induced cell death. Although the cleaved caspase 9 levels were
increased after exposure to Dermaseptin‐PS1, the caspase 9 level
was also increased compared with the positive control etoposide
treatment. We suspect that, apart from activation of caspase 9,
Dermaseptin‐PS1 could also increase the expression of this gene,
which culminates in elevation of both caspase 9 and its cleaved
form.
Overall, our study not only provides new candidate for
the treatment of malignant glioblastoma, but also illuminates
F IGURE 5 The examinations of extrinsic apoptotic cascade
mediated by Dermaseptin‐PS1 in U‐251 MG cells. Protein expression
of caspase 8/cleaved caspase 8 and FADD were analysed by
Western blot in U‐251 MG cells treated for 4‐24 h with 10−6 M
Dermaseptin‐PS1 or 16‐24 h with 20 μmol/L etoposide. The
detection of GAPDH protein was used as an internal control
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insights into the preliminary mechanism by which Dermaseptin‐
PS1 induces U‐251 MG cells intrinsic apoptosis at the specific
10−6M concentration. Therefore, we emphasise that precisely
control the dose of the prescription in clinic might be another
perspective research area for achieving our ultimate goal of can-
cer treatment.
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F IGURE 6 Dermaseptin‐PS1 induced U‐251 MG cell death through intrinsic apoptosis signalling. A, Protein expression of caspase 9/cleaved
caspase 9, Apaf‐1, Bcl‐2, Bax, Bak, p‐Bad, Bad, p‐p53 and p53 were analysed by Western blot in U‐251 MG cells treated for 4‐24 h with
10−6 M Dermaseptin‐PS1 or 16‐24 h with 20 μmol/L etoposide. The detection of GAPDH protein was used as an internal control. The signal
intensity was quantified by Image Lab software and GraphPad Prism 5 software was used for statistical comparison. NC, negative control. *or
#P < 0.01, ** or ##P < 0.05 and *** or ###P < 0.001 vs NC. B, Cytochrome c release from the mitochondria into the cytosol was measured via
Western blot. COX IV was used as a loading control for mitochondrial fractions. The signal intensity was quantified by Image Lab software and
GraphPad Prism 5 software was used for statistical comparison. NC, negative control; PS1, Dermaseptin‐PS1; Eto, etoposide. *P < 0.05 vs
protein expression in cytosol after etoposide treatment; ###P < 0.001 vs protein expression in cytosol after Dermaseptin‐PS1 treatment
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